2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea.
Mee Kyoung KimSeung Hyun KoBo Yeon KimEun Seok KangJunghyun NohSoo Kyung KimSeok O ParkKyu Yeon HurSuk ChonMin Kyong MoonNan Hee KimSang Yong KimSang Youl RheeKang Woo LeeJae Hyeon KimEun Jung RheeSungWan ChunSung Hoon YuDae Jung KimHyuk-Sang KwonKyong Soo Parknull nullPublished in: Diabetes & metabolism journal (2020)
The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations.